Acorda Therapeutics announced the U.S. Food and Drug Administration (FDA) approved INBRIJA for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa.....
Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration approved Inbrija? for intermittent treatment of OFF episodes in people with ....
Acorda Therapeutics reported Thursday that the FDA extended its review of a filing seeking clearance of Inbrija (levodopa) by three months to January 5, 2019.